Search clinical trials for: Computer Assisted Learning (CAL) Module

Total 1746 results

Emory University
National Cancer Institute (NCI); Genentech, Inc.

Suspended

Pre-operative Atezolizumab in Patients With Resectable, Human Papillomavirus Related Oropharyngeal Carcinoma

Oropharynx Cancer, Stage I

United States
US Department of Veterans Affairs

Terminated

Nicotine Delivery Systems: Research & Treatment (NDS)

Smoking

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual Treatment (Radiation Therapy and Temozolomide) for Advanced Brain Cancer

Advanced Glioblastoma
OHSU Knight Cancer Institute
Oregon Health and Science University; Eisai Inc.

Active, not recruiting

Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery

Malignant Solid Neoplasm | Liposarcoma | Malignant Abdominal Neoplasm | Malignant Retroperitoneal Neoplasm | Malignant Scrotal Neoplasm | Malignant Spermatic Cord Neoplasm

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer

Oropharyngeal Cancer | Malignant Neoplasms of Lip Oral Cavity and Pharynx

United States
National Cancer Institute (NCI)

Completed

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Lymphoma | Non-Hodgkin Lymphoma | NHL | Hematologic Malignancies | Lymphoid Malignancies

United States
National Cancer Institute (NCI)

Active, not recruiting

HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers

Cervical Cancer | Anal Cancer | Oropharyngeal Cancer | Vulvar, Vaginal, Penile, Rectal Cancer | HPV Positive Cancer

United States
University of Michigan Rogel Cancer Center
Neuroendocrine Research Foundation

Recruiting

An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer

Neuroendocrine Tumor

United States
Mayo Clinic

Recruiting

Grid Radiation Therapy for the Treatment of Stage IV Non-Small Cell Lung Cancer

Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
University of Michigan Rogel Cancer Center
Incyte Corporation

Recruiting

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
Northwestern University
National Cancer Institute (NCI)

Recruiting

XL092 (Zanzalintinib) for the Treatment of Patients With Metastatic or Unresectable Leiomyosarcoma

Metastatic Leiomyosarcoma | Unresectable Leiomyosarcoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma

Malignant Solid Neoplasm | Melanoma | Renal Cell Carcinoma | Lung Non-Small Cell Carcinoma

United States
University of Southern California
National Cancer Institute (NCI); Auransa, Inc.

Recruiting

AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Advanced Hepatocellular Carcinoma | Metastatic Malignant Neoplasm in the Liver | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Advanced Cholangiocarcinoma

United States
Yale University
ViiV Healthcare

Active, not recruiting

Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs

Hiv

United States
University of Washington
Novartis; Society of Nuclear Medicine and Molecular Imaging (SNMMI) Mars Shot...

Recruiting

Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease

Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-Resistant Prostate Carcinoma

United States
University of California, San Francisco
National Institute of Allergy and Infectious Diseases (NIAID); San Francisco... and other collaborators

Recruiting

Multidisciplinary Low-Barrier and Mobile HIV Care to Improve Retention and Viral Suppression: Stakeholder-Engaged Design and Evaluation

HIV

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Cervical Cancer

United States, Hong Kong, Canada, South Korea
Joseph J. Cullen
Gateway for Cancer Research; Holden Comprehensive Cancer Center

Completed

Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I

Pancreatic Neoplasms

United States
LMC Diabetes & Endocrinology Ltd.
Merck Sharp & Dohme LLC; Syreon Corporation

Withdrawn

Approaches To Therapy Escalation In T2D (ATTACC)

Type2 Diabetes
Andrei Iagaru

No longer available

F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | PSA Progression | PSA Level Greater Than or Equal to Two | PSA Level Greater Than 0.2

United States
Sanjiv Sam Gambhir

Terminated

Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer

Breast Carcinoma | Ovarian Carcinoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Exelixis

Not yet recruiting

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Locally Advanced Hepatocellular Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

Locally Advanced Lung Neuroendocrine Neoplasm | Lung Neuroendocrine Neoplasm | Metastatic Lung Neuroendocrine Neoplasm | Recurrent Lung Neuroendocrine Neoplasm | Unresectable Lung Neuroendocrine Neoplasm | Advanced Lung Neuroendocrine Tumor | Functioning Lung Neuroendocrine Tumor | Lung Neuroendocrine... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer

Lung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia | Hairy Cell Leukemia Variant | Recurrent Hairy Cell Leukemia Variant

United States
University of Washington
Regeneron Pharmaceuticals

Recruiting

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Recurrent High Grade B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

Burkitt Lymphoma | Double-Expressor Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

Metastatic Leiomyosarcoma | Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Advanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Advanced Leiomyosarcoma | Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Advanced Dedifferentiated Liposarcoma | Metastatic...

United States
National Cancer Institute (NCI)

Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

Pancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma | Resectable Pancreatic Acinar Cell Carcinoma | Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic Carcinoma

United States, Puerto Rico, Israel
National Cancer Institute (NCI)

Active, not recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial

Malignant Solid Neoplasm | Adrenal Gland Pheochromocytoma | Paraganglioma | Hematopoietic and Lymphatic System Neoplasm

United States
Seema Bhat
AstraZeneca; Acerta Pharma, LLC

Recruiting

Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

United States
Emory University
National Cancer Institute (NCI)

Recruiting

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Adrenal Cortical Carcinoma | Stage III Adrenal Cortex Carcinoma | Stage IV Adrenal Cortex Carcinoma AJCC v8 | Unresectable Adrenal Cortex Carcinoma | Locally Advanced Adrenal Cortex Carcinoma

United States
Jonsson Comprehensive Cancer Center
American Cancer Society, Inc.; LUNGevity Foundation

Recruiting

An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer

Lung Adenocarcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors

Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Unresectable Melanoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers

Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis

Hepatocellular Carcinoma | Cirrhosis

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma

United States
New Lexington Clinic
Zimmer Biomet

Terminated

Postoperative Function Following Partial and Total Knee Replacement

Osteoarthritis | Post-traumatic Arthritis

United States
National Cancer Institute (NCI)

Active, not recruiting

Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions

United States
Washington University School of Medicine

Completed

Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)" (MINT)

HPV Related Oropharyngeal Squamous Cell Carcinoma

United States
University of Washington
National Cancer Institute (NCI); United States Department of Defense

Active, not recruiting

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
National Cancer Institute (NCI)

Completed

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Advanced Bladder Urothelial Carcinoma | Advanced Ureter Urothelial Carcinoma | Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Recurrent Bladder... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Active, not recruiting

A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma

Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Uterine Corpus Leiomyosarcoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Not yet recruiting

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Astrocytoma, IDH-Mutant, Grade 3
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Single Fraction or Multi-fraction Palliative Radiation Therapy for the Improvement of Quality of Life in Patients With Metastatic Gynecologic Cancers

Metastatic Malignant Female Reproductive System Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer

Human Papillomavirus Infection | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage I Oropharyngeal Squamous Cell Carcinoma | Stage II Oropharyngeal Squamous Cell Carcinoma | Stage III Oropharyngeal Squamous Cell Carcinoma

United States

Search clinical trials for: Computer Assisted Learning (CAL) Module

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations